Abstract
<jats:p>This publication provides a timely and authoritative assessment of the delivery platforms enabling the next wave of RNA-based medicines. Drawing on expertise from leading biopharmaceutical manufacturers and suppliers, the paper evaluates the strengths, limitations and development considerations of lipid nanoparticles (LNPs), liposomes, exosomes, polymer-based systems and emerging hybrid technologies. Readers will gain practical insights into key industry challenges, including tissue targeting, stability, manufacturability, scale-up, product characterization, regulatory expectations and cost of goods. The report also benchmarks the comparative advantages and risks of different delivery approaches, helping organizations make more informed technology and development decisions. This BioPhorum paper provides a comprehensive comparison of the leading RNA delivery technologies, including lipid nanoparticles (LNPs), liposomes, exosomes and polymer-based systems, helping readers understand their relative strengths, limitations and commercial readiness. It explores key considerations such as manufacturability, scalability, tissue targeting, stability and product quality, while highlighting emerging approaches that could shape the future of RNA medicines and vaccines. Developed through collaboration between experts from across the global biopharmaceutical industry, the paper offers valuable insights into the barriers, opportunities and innovations driving the next generation of RNA therapeutics. This publication demonstrates BioPhorum’s unique role in convening industry experts to address critical scientific and manufacturing challenges, helping transform RNA delivery from an emerging technology into a scalable and commercially viable reality.</jats:p>